In-Body CAR-T: a new shot at fighting blood cancers?
NCT ID NCT07511426
First seen Apr 21, 2026 · Last updated Jun 19, 2026 · Updated 13 times
Summary
This early study tests a new treatment called U96 for people with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. U96 is a gene therapy given as a single infusion that aims to create cancer-fighting CAR-T cells inside the patient's own body. The trial will enroll about 30 adults and focus first on safety, checking for side effects and how well the treatment is tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL LEUKEMIA AND LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
U96 (a gene therapy that creates CAR-T cells inside the body to target CD19 on cancer cells)
What this could lead to
If it works, this could offer a new treatment option for patients with hard-to-treat B-cell cancers, potentially reducing the need for complex lab-made CAR-T cells.
What could go wrong
This is a very early Phase 1 trial with only 30 patients, so it is too soon to know if it is safe or effective. There are risks of serious side effects like cytokine release syndrome and nerve problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.